Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-12 pm EST			After hours 04:35:59 pm
40.11 ^USD	-0.99%		40.20	+0.22%

07:17am	PRESS DIGEST-New York Times business news - February 12	RE
Feb. 11	Wall Street gains muted after strong jobs data nibbles at Fed rate cut bets	RE

Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year

Published on 01/12/2026 at 10:47 am EST

MT Newswires

Latest news about Moderna, Inc.

07:17am	PRESS DIGEST-New York Times business news - February 12	RE
Feb. 11	Wall Street gains muted after strong jobs data nibbles at Fed rate cut bets	RE
Feb. 11	S&P 500, Dow muted after jobs data; Alphabet, Microsoft drag on Nasdaq	RE
Feb. 11	Wall Street climbs in broad rally after stronger-than-expected jobs report	RE
Feb. 11	Moderna shares pare losses; last down down 3.8%	RE
Feb. 11	Wall St set to open higher after stronger-than-expected jobs report	RE
Feb. 11	Leerink Partners Adjusts Moderna PT to $12 From $17, Maintains Underperform Rating	MT
Feb. 11	Fda's Vinay Prasad overruled staff to reject Moderna's flu vaccine application - Stat News	RE
Feb. 11	Moderna in a Spin After FDA Declines to Review Flu Vaccine Candidate
Feb. 11	US stock futures stall in run-up to January jobs data	RE
Feb. 11	Goldilocks Jobs, Jittery Markets
Feb. 11	Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010	CI
Feb. 11	North American Morning Briefing : Futures Mostly Decline; Investors Wait for Jobs Data	DJ
Feb. 11	Wall Street ends muted after strong jobs data nibbles at Fed rate cut bets	RE
Feb. 11	Moderna Seasonal Flu Vaccine Application Faces FDA Review Refusal; Shares Fall Pre-Bell	MT
Feb. 11	PRESS DIGEST-Wall Street Journal - February 11	RE
Feb. 10	Moderna Stock Slips After FDA Refuses Flu Vaccine Review	DJ
Feb. 10	FDA refuses to review Moderna's influenza vaccine application	RE
Feb. 10	Moderna: receives refusal-to-file letter from U.S. Food and Drug Administration for its investigational seasonal influenza vaccine, mRNA-1010	RE
Feb. 10	Fda refuses to consider approving use of Moderna's new flu vaccine - WSJ	RE
Feb. 10	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
Feb. 10	Sector Update: Health Care Stocks Mixed Tuesday Afternoon	MT
Feb. 10	Sector Update: Health Care	MT
Feb. 10	Moderna Signs Long-Term mRNA Manufacturing Agreement With Mexican Government	MT
Feb. 09	Dow Hits New High Amid Tech-Led Advance	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

Feb. 12 - Q4 2025 Earnings Release

More about the company